Table 4.
Distribution of EGFR and KRAS Mutations According to Histologic Subtypes and Pathologic Stage
| EGFR and KRAS Mutations | Total Number = 512, n (%) |
|---|---|
| EGFR mutations, n | 201 |
| Histologic subtypes | |
| Adenocarcinoma | 196 (97.5) |
| Papillary predominant | 119 (59.2) |
| Acinar predominant | 35 (17.5) |
| Lepidic predominant | 24 (11.9) |
| Solid predominant | 18 (8.9) |
| Pleomorphic | 1 (0.5) |
| Adenosquamous | 2 (1) |
| Squamous | 1 (0.5) |
| Clear cell | 1 (0.5) |
| Pathologic stage | |
| IA | 132 (65.7) |
| IB | 17 (8.5) |
| IIA | 4 (1.9) |
| IIB | 21 (10.4) |
| IIIA | 27 (13.5) |
| KRAS mutations, n | 42 |
| Histologic subtypes | |
| Adenocarcinoma | 35 (83.4) |
| Papillary predominant | 12 (28.5) |
| Invasive mucinous | 11 (26.1) |
| Lepidic predominant | 3 (7.1) |
| Solid predominant | 3 (7.1) |
| Acinar predominant | 1 (2.3) |
| Large | 7 (16.6) |
| Pathologic stage | |
| IA | 17 (40.4) |
| IB | 7 (16.7) |
| IIA | 3 (7.2) |
| IIB | 8 (19.0) |
| IIIA | 7 (16.7) |